SXTP — 60 Degrees Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareMicro Cap
- $3.16m
- $11.77m
- $1.41m
60 Degrees Pharma withdraws mid-stage study application for COVID drug
Brief: 60 Degrees Pharmaceuticals Registers Aclr8-Lr, A Phase Iib Study Of Tafenoquine For Treatment Of Covid-19, On Clinicaltrials.Gov
Brief: 60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine
Brief: 60 Degrees Pharmaceuticals Announces Pricing Of Initial Public Offering